347 related articles for article (PubMed ID: 19522463)
21. Hedgehog antagonists cyclopamine and dihydroveratramine can be mistaken for each other in Veratrum album.
Wilson SR; Strand MF; Krapp A; Rise F; Herstad G; Malterud KE; Krauss S
J Pharm Biomed Anal; 2010 Nov; 53(3):497-502. PubMed ID: 20646889
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and anticancer activity studies of cyclopamine derivatives.
Zhang J; Garrossian M; Gardner D; Garrossian A; Chang YT; Kim YK; Chang CW
Bioorg Med Chem Lett; 2008 Feb; 18(4):1359-63. PubMed ID: 18221872
[TBL] [Abstract][Full Text] [Related]
23. One Hundred Faces of Cyclopamine.
Iovine V; Mori M; Calcaterra A; Berardozzi S; Botta B
Curr Pharm Des; 2016; 22(12):1658-81. PubMed ID: 26759083
[TBL] [Abstract][Full Text] [Related]
24. Cyclopamine bioactivity by extraction method from Veratrum californicum.
Turner MW; Cruz R; Mattos J; Baughman N; Elwell J; Fothergill J; Nielsen A; Brookhouse J; Bartlett A; Malek P; Pu X; King MD; McDougal OM
Bioorg Med Chem; 2016 Aug; 24(16):3752-7. PubMed ID: 27338657
[TBL] [Abstract][Full Text] [Related]
25. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility.
Ohashi T; Oguro Y; Tanaka T; Shiokawa Z; Tanaka Y; Shibata S; Sato Y; Yamakawa H; Hattori H; Yamamoto Y; Kondo S; Miyamoto M; Nishihara M; Ishimura Y; Tojo H; Baba A; Sasaki S
Bioorg Med Chem; 2012 Sep; 20(18):5507-17. PubMed ID: 22898254
[TBL] [Abstract][Full Text] [Related]
26. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway.
Gould A; Missailidis S
Mini Rev Med Chem; 2011 Mar; 11(3):200-13. PubMed ID: 21222574
[TBL] [Abstract][Full Text] [Related]
27. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.
Ontoria JM; Bufi LL; Torrisi C; Bresciani A; Giomini C; Rowley M; Serafini S; Bin H; Hao W; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2011 Sep; 21(18):5274-82. PubMed ID: 21803580
[TBL] [Abstract][Full Text] [Related]
28. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth.
Campbell VT; Nadesan P; Ali SA; Wang CY; Whetstone H; Poon R; Wei Q; Keilty J; Proctor J; Wang LW; Apte SS; McGovern K; Alman BA; Wunder JS
Mol Cancer Ther; 2014 May; 13(5):1259-69. PubMed ID: 24634412
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective synthesis of F-ring saturated estrone-derived inhibitors of Hedgehog signaling based on cyclopamine.
Zhang Z; Baubet V; Ventocilla C; Xiang C; Dahmane N; Winkler JD
Org Lett; 2011 Sep; 13(18):4786-9. PubMed ID: 21842835
[TBL] [Abstract][Full Text] [Related]
30. A looking glass perspective: thalidomide and cyclopamine.
Gaffield W; Incardona JP; Kapur RP; Roelink H
Cell Mol Biol (Noisy-le-grand); 1999 Jul; 45(5):579-88. PubMed ID: 10512190
[TBL] [Abstract][Full Text] [Related]
31. I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs.
Chen JK
Nat Prod Rep; 2016 May; 33(5):595-601. PubMed ID: 26787175
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor.
Guerlet G; Spangenberg T; Mann A; Faure H; Ruat M
Bioorg Med Chem Lett; 2011 Jun; 21(12):3608-12. PubMed ID: 21592788
[TBL] [Abstract][Full Text] [Related]
33. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.
Feldmann G; Fendrich V; McGovern K; Bedja D; Bisht S; Alvarez H; Koorstra JB; Habbe N; Karikari C; Mullendore M; Gabrielson KL; Sharma R; Matsui W; Maitra A
Mol Cancer Ther; 2008 Sep; 7(9):2725-35. PubMed ID: 18790753
[TBL] [Abstract][Full Text] [Related]
34. Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives.
Heretsch P; Tzagkaroulaki L; Giannis A
Angew Chem Int Ed Engl; 2010 May; 49(20):3418-27. PubMed ID: 20429080
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of several dietary alkaloids as weak inhibitors of hedgehog signaling.
Lipinski RJ; Dengler E; Kiehn M; Peterson RE; Bushman W
Toxicol Sci; 2007 Dec; 100(2):456-63. PubMed ID: 17728282
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog inhibition with cyclopamine represses tumor growth and prolongs survival in a transgenic mouse model of islet cell tumors.
Fendrich V; Rehm J; Waldmann J; Buchholz M; Christofori G; Lauth M; Slater EP; Bartsch DK
Ann Surg; 2011 Mar; 253(3):546-52. PubMed ID: 21239987
[TBL] [Abstract][Full Text] [Related]
37. Tumor shrinkage by cyclopamine tartrate through inhibiting hedgehog signaling.
Fan Q; Gu D; He M; Liu H; Sheng T; Xie G; Li CX; Zhang X; Wainwright B; Garrossian A; Garrossian M; Gardner D; Xie J
Chin J Cancer; 2011 Jul; 30(7):472-81. PubMed ID: 21718593
[TBL] [Abstract][Full Text] [Related]
38. Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse.
Lipinski RJ; Hutson PR; Hannam PW; Nydza RJ; Washington IM; Moore RW; Girdaukas GG; Peterson RE; Bushman W
Toxicol Sci; 2008 Jul; 104(1):189-97. PubMed ID: 18411234
[TBL] [Abstract][Full Text] [Related]
39. Cyclopamine: from cyclops lambs to cancer treatment.
Lee ST; Welch KD; Panter KE; Gardner DR; Garrossian M; Chang CW
J Agric Food Chem; 2014 Jul; 62(30):7355-62. PubMed ID: 24754790
[TBL] [Abstract][Full Text] [Related]
40. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
Bisht S; Brossart P; Maitra A; Feldmann G
Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
